BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have
advanced solid tumors that have not responded to previous therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb R-Pharm
Collaborators:
Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI)